Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Prostatic Neoplasms 19Glioblastoma 18Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 12Rectal Neoplasms 11Oropharyngeal Neoplasms 10Neoplasms 9Head and Neck Neoplasms 8Glioma 8Astrocytoma 8Neoplasm Metastasis 7Sarcoma 6Esophageal Neoplasms 6Carcinoma, Squamous Cell 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Lymphoma, Follicular 5Hodgkin Disease 5Gliosarcoma 5Esophageal Squamous Cell Carcinoma 5Carcinoma 5Burkitt Lymphoma 5Brain Neoplasms 5Adenocarcinoma of Lung 5Adenocarcinoma Of Esophagus 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Nasopharyngeal Carcinoma 4

Interventions

Cyclophosphamide 12Vincristine 9Etoposide 8venetoclax 6Methotrexate 6Doxorubicin 6Dexamethasone 6Cytarabine 6Prednisone 5Calcium Dobesilate 5prednylidene 4pegaspargase 4merphos 4dexamethasone acetate 4dexamethasone 21-phosphate 4deltacortene 4calaspargase pegol 4auricularum 4Specimen Handling 4Granulocyte Colony-Stimulating Factor 4fludarabine phosphate 3daratumumab 3Thioguanine 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Mercaptopurine 3Magnetic Resonance Spectroscopy 3Leucovorin 3Hydrocortisone 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Radiotherapy × 90 days × Clear all
NCT02112916 2026-06-03

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
847 enrolled 19 charts
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡